Levosimendan Eg

Active Ingredient:: Levosimendan
Origin:: EU

Levosimendan Eg (Levosimendan)

Q: What is Levosimendan Eg used for?

Levosimendan Eg is used to treat acute decompensated heart failure and other severe heart‑failure states where rapid improvement of cardiac contractility and vasodilation are required. It is administered intravenously under medical supervision to stabilize haemodynamics in hospitalized patients.

Q: How does levosimendan work?

Levosimendan enhances the heart’s contractile force by sensitising troponin C to calcium, allowing stronger contractions without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that reduces cardiac after‑load and improves overall cardiac output.

Q: What is the usual dose of Levosimendan Eg?

The dosing regimen for Levosimendan Eg is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. Healthcare professionals calculate the appropriate infusion rate and duration according to approved guidelines and individual patient needs.

Q: Is Levosimendan safe during pregnancy or breastfeeding?

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

Q: How do I order Levosimendan Eg from GNH India?

To order Levosimendan Eg, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Q: How does levosimendan compare with other inotropes?

Unlike traditional catecholamine inotropes, levosimendan increases contractility without raising intracellular calcium, which may reduce the risk of arrhythmias. Its combined vasodilatory effect also lowers after‑load, offering a distinct haemodynamic profile compared with agents such as dobutamine or milrinone.

Q: What are the storage and handling requirements for Levosimendan Eg?

Levosimendan Eg should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability before preparation for intravenous infusion.

Q: How is Levosimendan Eg administered?

Levosimendan Eg is given by intravenous infusion, typically initiated with a loading dose followed by a continuous maintenance infusion. Administration is performed in a hospital setting where cardiac monitoring and blood pressure checks can be conducted throughout the infusion period.

Q: What are the most serious risks associated with Levosimendan Eg?

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Continuous cardiovascular monitoring is essential to detect and manage these events promptly during therapy.

Q: Who should not receive Levosimendan Eg?

Levosimendan Eg is contraindicated in patients with systolic blood pressure below 90 mmHg, severe obstructive cardiac lesions, or known hypersensitivity to the drug. Caution is also advised for individuals with significant renal or hepatic impairment, and the decision to treat should be made by a qualified clinician.

Levosimendan, the active ingredient in Levosimendan Eg, is a calcium sensitizer / potassium channel opener presented as a strength/form for intravenous use. It treats acute decompensated heart failure in adult patients who require rapid improvement of cardiac output.
GNH India supplies Levosimendan Eg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Eg S.P.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan is used in the management of heart failure syndromes where enhanced cardiac contractility and vasodilation are needed.

Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion.
Severe chronic heart failure with low output: provides hemodynamic support when conventional therapy is insufficient.
Low cardiac output syndrome after cardiac surgery: stabilises haemodynamics during the postoperative period.

How It Works

Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby enhancing myocardial contractility without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing after‑load, which together improve cardiac output and tissue perfusion.

Side Effects

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects

Headache: mild to moderate intensity.
Hypotension: transient blood pressure reduction.
Nausea: occasional gastrointestinal upset.
Tachycardia: increased heart rate.
Flushing: warm sensation and skin reddening.
Arrhythmia: non‑sustained ventricular ectopy.

Serious or Rare Side Effects

Severe hypotension: may require vasopressor support.
Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
Myocardial ischemia: chest pain or ECG changes.
Allergic reactions: rash, pruritus, or anaphylaxis.
Liver enzyme elevation: transient increase in transaminases.
Thrombocytopenia: reduced platelet count.

Precautions & Warnings

Levosimendan requires careful monitoring and specific safety considerations before and during administration.

Blood pressure monitoring: watch for significant hypotension.
Cardiac rhythm surveillance: detect arrhythmias promptly.
Renal impairment: adjust use in patients with reduced clearance.
Hepatic impairment: use cautiously in liver disease.
Contraindication in severe hypotension: avoid in patients with systolic BP <90 mmHg.
Store at ambient temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Levosimendan can interact with other cardiovascular agents, necessitating vigilance.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels.
Concurrent inotropes (e.g., dobutamine): risk of excessive cardiac stimulation.
Potent vasodilators (e.g., nitroglycerin): may cause profound hypotension.

Moderate Interactions (Monitor Closely)

Diuretics: monitor electrolytes and volume status.
ACE inhibitors or ARBs: watch for additive blood pressure effects.
Beta‑blockers: assess heart rate and contractility.
Calcium channel blockers: observe for combined vasodilatory impact.
Anticoagulants (e.g., warfarin): monitor coagulation parameters.

Frequently Asked Questions

Levosimendan Eg is used to treat acute decompensated heart failure and other severe heart‑failure states where rapid improvement of cardiac contractility and vasodilation are required. It is administered intravenously under medical supervision to stabilize haemodynamics in hospitalized patients.

Levosimendan enhances the heart’s contractile force by sensitising troponin C to calcium, allowing stronger contractions without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that reduces cardiac after‑load and improves overall cardiac output.

The dosing regimen for Levosimendan Eg is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. Healthcare professionals calculate the appropriate infusion rate and duration according to approved guidelines and individual patient needs.

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Levosimendan Eg, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility without raising intracellular calcium, which may reduce the risk of arrhythmias. Its combined vasodilatory effect also lowers after‑load, offering a distinct haemodynamic profile compared with agents such as dobutamine or milrinone.

Levosimendan Eg should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability before preparation for intravenous infusion.

Levosimendan Eg is given by intravenous infusion, typically initiated with a loading dose followed by a continuous maintenance infusion. Administration is performed in a hospital setting where cardiac monitoring and blood pressure checks can be conducted throughout the infusion period.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Continuous cardiovascular monitoring is essential to detect and manage these events promptly during therapy.

Levosimendan Eg is contraindicated in patients with systolic blood pressure below 90 mmHg, severe obstructive cardiac lesions, or known hypersensitivity to the drug. Caution is also advised for individuals with significant renal or hepatic impairment, and the decision to treat should be made by a qualified clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.